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Abstract
Respiratory viral infections are a leading cause of disease and mortality. The severity of these illnesses can vary
markedly from mild or asymptomatic upper airway infections to severe wheezing, bronchiolitis or pneumonia. In
this article, we review the viral sensing pathways and organizing principles that govern the innate immune response to
infection. Then, we reconstruct the molecular networks that differentiate symptomatic from asymptomatic respiratory
viral infections, and identify the underlying molecular drivers of these networks. Finally, we discuss unique aspects of
the biology and pathogenesis of infections with respiratory syncytial virus, rhinovirus and influenza, drawing on insights
from genomics.
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Background
Respiratory infections are the leading cause of disease
globally [1]. In young children, they are responsible for
around one quarter of hospitalizations and up to 60% of
visits to the general practitioner [2]. In most cases, re-
spiratory viral infections are self-limiting and confined
to the upper airways, where they evoke relatively mild
symptoms such as sneezing and a runny nose [3]. However,
in susceptible individuals, such as newborns and the elderly,
the symptoms can impact on the lower airways, resulting in
wheeze, shortness of breath, bronchiolitis or pneumonia
[4]. Common respiratory viral pathogens include adeno-
virus, enterovirus, human coronavirus, human metapneu-
movirus, rhinovirus (RV), influenza, parainfluenza and
respiratory syncytial virus (RSV). Of these viruses, most
genomic studies have focused on RSV, RV and influenza.
This is because RSV is the most important cause of respira-
tory tract infections leading to hospitalization among in-
fants [5]. RV causes the majority of colds and around two
thirds of asthma exacerbations [6]. Influenza is the most
common cause of pneumonia related deaths in developed
countries [7]. The mechanisms that determine why some
individuals suffer from severe illness whilst others do not
are not well understood. In this review we will focus
primarily on the contribution of the host response, drawing
on insights from genomics.
Gene expression profiling technologies
The advent of microarrays enabled the measurement of
gene expression patterns on a genome-wide scale [8].
Microarrays comprise a vast array of oligonucleotide
probes of 25 bases or more in length, fixed to a solid
surface. The probes bind to labelled target molecules
(e.g. cDNA derived from mRNA), and the signal inten-
sity is quantified. Despite this major technological ad-
vance, cross-hybridization of related sequences limited
the signal-to-noise ratio [9]. Microarrays are slowly
being phased out and superseded by deep sequencing
technologies for gene expression profiling (RNA-Seq).
RNA-Seq entails the generation of a library of cDNA
fragments from total RNA or mRNA, followed by ligation
of adapters, PCR amplification and high throughput se-
quencing [10]. This generates millions of short sequencing
reads (e.g. 50–200 bases), which are aligned to a reference
genome sequence, and summarized as gene- or transcript-
level counts. Compared with microarrays, advantages of
RNA-Seq include single base resolution, superior sensi-
tivity and dynamic range, and the ability to detect novel
transcripts. The data from microarray and RNA-Seq ex-
periments is typically submitted to a public repository
at the time of publication (e.g. Gene Expression Omnibus;
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ive; www.ncbi.nlm.nih.gov/sra), allowing other researchers
to freely access the data for reanalyses [11].
Network analysis of genomic data
Most genomic studies focus on identification of differen-
tially expressed genes. However, this approach is limited,
because genes do not exist nor function in isolation, they
work together [12]. A significant advance in this context
was the application of network graph theory to genomic
data analysis [13]. The underlying concept is that a func-
tioning biological system can be represented as a network
of interconnected nodes and links. The nodes represent
genes or their products (mRNA transcripts, proteins) and
the links represent functional or statistical relationships
between genes. For instance, the links could represent
physical binding interactions between proteins, or coex-
pression relationships between mRNA transcripts. Gene
networks have a non-uniform, so-called “scale-free” top-
ology, where most genes are connected to few genes, and
a few genes are connected to many [14]. This results in a
limited number of highly connected nodes called hubs,
which essentially “hold” the network together [14]. An
emergent property of scale-free networks is a tolerance to
random perturbations and a susceptibility to the dis-
ruption of hubs [13]. Another fundamental organizing
principle of gene networks is modularity, meaning that
genes which function in the same biological process
form densely interconnected subgraphs embedded within
the network structure [15]. Modules execute biological
tasks, and the breakdown of functional modules is thought
to underpin disease states [16].
Respiratory viral pathogens and entry mechanisms
RSV is an enveloped, single strand, negative sense RNA
virus of the family Paramyxoviridae. There are two anti-
genic subtypes (RSV-A, RSV-B). The genome encodes
seven structural proteins and four non-structural proteins.
The envelope is encoded by three glycoproteins, namely
the small hydrophobic protein, the attachment protein G
and the fusion protein F. Virus entry is mediated by bind-
ing of the F protein to host-cell nucleolin [17].
RV is a non-enveloped, single strand, positive sense
RNA virus belonging to the Picornaviridae family. It is
contained within an icosahedral capsid, encoded by four
viral proteins (VP1-VP4). More than 160 strains have
been identified, and these are classified into three species
(RV-A, −B, −C) on the basis of genome sequence. RV-B
and most RV-A strains bind intercellular adhesion mol-
ecule (ICAM1) on the cell surface to gain entry. A sub-
group of RV-A strains bind to low-density lipoprotein
receptor (LDLR) family members for virus entry [18].
The entry mechanism for RV-C remained elusive until
recently. Using microarrays, it was demonstrated that
expression of cadherin-related family member 3 (CDHR3)
was upregulated in cells that were susceptible to RV-C
versus cells that were resistant [19]. Moreover, ectopic
expression of CDHR3 in resistant cells conferred sus-
ceptibility to infection.
Influenza is an enveloped virus from the Orthomyoxoviri-
dae family. The genome is composed of eight segments of
single strand, negative sense RNA. It is classified into three
subtypes (A, B, C). Influenza A virus (IAV) is the major
subtype that circulates in humans, but it can also infect a
diverse range of hosts including mammals and birds. The
IAV genome encodes 11 proteins; hemagglutinin (HA),
neuraminidase (NA), nucleoprotein (NP), matrix proteins
(M1, M2), non-structural proteins (NS1, NS2), polymerase
proteins (PB1, PB2, PA), and PB1-F2 and is further classi-
fied based on the HA and NA glycoproteins found on the
viral envelope. Glycans containing sialic acid mediate IAV
attachment. Seasonal IAV binds to ASα2-6Gal, which are
found primarily on the surface of epithelial cells in the nasal
mucosa, trachea and bronchi. In contrast, highly pathogenic
avian H5N1 virus binds to ASα2-3Gal, which is found on
alveolar epithelial cells [20].
Innate immune sensing of viral infections
The airway epithelium is the primary site for viral infec-
tion and replication. Viruses must first penetrate the
mucus layer, which provides a first line of defence against
invading pathogens. When this mechanism fails, the in-
nate immune system is activated. Innate immunity re-
lies on a series of germ-line encoded receptors that are
expressed on epithelial and innate immune cells. These
pattern recognition receptors (PRR) are sensors for
pathogen-derived, evolutionarily conserved molecular
structures, known as pathogen- or microbe-associated
molecular patterns (PAMP/MAMP). PRR can also detect
endogenous molecules called damage-associated molecu-
lar patterns (DAMP). DAMPs are normally sequestered,
but released from damaged, dying or infected cells to alert
the immune system to the presence of “danger”. There are
four major classes of PRR; the Toll-like receptors (TLR),
nucleotide-binding oligomerization domain (NOD)-like
receptors (NLRs), retinoic acid-inducible gene-I (RIG-1)-
like receptors (RLR), and C-type lectin receptors (CLR).
Most TLRs are expressed at the cell surface (TLR1, −2,
−4, −5, −6, 10), where they interact with bacterial compo-
nents and viral proteins. For instance, TLR2 is a sensor for
bacterial peptidoglycans, lipoproteins, RSV and RV capsid
[21, 22]. TLR4 is a sensor for bacterial lipopolysaccharide
and RSV F protein, and also responds to DAMPs (e.g.
oxidized phospholipids, HMBG1, S100A9) during IAV
infection. However, these responses are thought to be
detrimental to the host as antagonizing TLR4 signalling
during IAV infection can protect mice from lethal dis-
ease [23–25]. The remaining TLRs (TLR3, −7, −8, −9)
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are expressed in endosomes, and RLRs (e.g. RIG-I,
MDA5) and NLRs are expressed in the cytoplasm. RNA
sensors that elicit responses to RSV include RIG-I,
TLR3, TLR7 and Nod2 (NLRC2) [26]. MDA5, TLR3,
TLR7, NLRX-1 and PKR mediate responses to RV RNA
[27–30]. IAV is detected by RIG-I, TLR3 and TLR7 [31].
The major viral sensing molecules are shown in Fig. 1.
Host responses to infection can also be triggered by fusion
between viral envelopes and the cell membrane, and
virus-induced endoplasmic reticulum stress [32–34].
Induction of proinflammatory and antiviral responses
PRR sensing of viruses triggers a series of intracellular
signaling cascades that converge on two major families of
transcription factors - nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) and interferon regu-
latory factor (IRF) (Fig. 1). These transcription factors
translocate to the nucleus where they upregulate their re-
spective proinflammatory and antiviral programs [35, 36].
The major signaling pathways involved are illustrated
in Fig. 1.
The interferon system is essential for immunity to most
viruses. Innate antiviral responses are primarily mediated
by type I (IFN-α, IFN-β) and type III interferons (IFN-λ1,
IFN-λ2, IFN-λ3), whereas type II interferon (IFN-γ) pro-
motes macrophage activation and Th1 differentiation [37].
Interferon signaling induces the expression of hundreds of
genes known collectively as interferon stimulated genes
(ISG, Fig. 1). Almost 1000 genes are upregulated by type I
interferon in one or more major immune cell populations,
Fig. 1 Viral sensing pathways that trigger host immune responses. PRR signalling is triggered by viral proteins and nucleic acids (PAMPs) and
host-derived DAMPs. All TLRs except TLR3 signal through the adapter molecule Myd88. TLR3 signals through TRIF, and TLR4 signals via both
Myd88- and TRIF-dependant pathways. RIGI, MDA5 and NOD2 signal through the mitochondrial antiviral-signaling protein MAVS (or IPS1). These
signalling pathways converge on IRF3/IRF7 and NFkB to activate their respective type I/III interferons and proinflammatory gene programs. Type I
(IFN-α, IFN-β) and III interferons (IFN-λ1, IFN-λ2, IFN-λ3 or IL-29, IL-28A, IL-28B) bind to distinct receptor complexes, which activates STAT1 and
STAT2 phosphorylation. IRF9 binds to STAT1/STAT2 heterodimers forming the ISGF3 complex, which translocates to the nucleus to induce
transcription of ISGs that contain ISRE elements in their promoters. Type II interferon signalling activates STAT1, which translocates to the
nucleus to induce transcription of ISGs containing GAS elements in their promoters. Some proinflammatory cytokines (pro-IL-1B, pro-IL-18)
are produced in an inactive form. The processing of these cytokines into their bioactive form is mediated by Capase-1, which is activated by
the NLRP3 inflammasome pathway
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and a core set of 166 genes are upregulated across all cell
types [38]. This core set includes archetypal ISGs (e.g. Mx
proteins, OAS, PKR, viperin), which induce a robust anti-
viral state to restrict viral replication and prevent the
spread of infection to neighboring cells. Mx proteins trap
viral components (e.g. IAV PB2 and nucleocapsid) pre-
venting nuclear import and viral replication. OAS activates
RNaseL, which degrades viral and cellular RNA. PKR
phosphorylates eukaryotic translation initiation factor
eIF2α to shut down the translation of cellular and viral
proteins. IFITM proteins block virus-host membrane fu-
sion in the endosome. Although the function of most ISGs
is unknown, high throughput functional screens suggest
that inhibition of viral translation is a common antiviral
strategy [39].
In addition to their classical antiviral function, inter-
ferons play diverse roles in infection. For example, inter-
feron signalling drives lymphopenia [40]. Interferons also
contribute to tissue injury by upregulating the expression
and release of TRAIL, which induces apoptosis in airway
epithelial cells [41]. Another emerging function is the pro-
motion of virus-induced sickness behavior and cognitive
dysfunction. This is mediated by upregulation of IFNAR1
on brain endothelial and epithelial cells, which in turn
produce CXCL10, and this signals via neuronal CXCR3 to
inhibit synaptic plasticity [42].
Molecular logic of the innate immune system
The molecular logic underlying innate immune responses
to environmental cues is governed by a bow-tie architecture
[43]. The bow-tie is an ordered control system, comprised
of three crucial elements: (i) input signals or “fan-in”; (ii)
the core or “knot”; and (iii) output signals or “fan-out”
(Fig. 2). Complex input signals are received by the core,
compressed and processed into simpler signalling pathways
and converted again to complex functional output signals.
Both input and output signals are highly variable, flexible,
robust and diverse. If one element fails, another can take
over and so the system is resistant to malfunctioning parts.
In contrast, the core is specialized, efficient and rigid. This
is important, because although the input and output layers
are perturbed by genetic variation, which creates a lot of
noise and complexity, ultimately a few core pathways are
critical for activation of the innate immune response. In-
deed, null mutations in core components like IRF7 can re-
sult in severe phenotypes [44]. Notably, these mutations are
extremely rare, which underscores the importance of this
pathway. This principle has been exploited by viruses,
which target core molecules to evade the host response.
For instance, RSV non-structural proteins suppress the acti-
vation and nuclear translocation of IRF3 [45], and inhibit
the interaction between RIG-I and MAVS, thus abrogating
the production of interferons [46]. IAV NS1 protein also in-
hibits IRF3 activation and interferon production [47].
Viral challenge studies
Viral challenge studies of adult volunteers with live re-
spiratory viruses provide a powerful model to identify
host responses underlying disease pathogenesis in vivo.
In these challenge models, around half of the inoculated
subjects develop respiratory symptoms and have con-
firmed viral shedding, whereas the remaining subjects
are asymptomatic [3, 48]. These studies have found that
symptomatic infections are associated with a heighted
immune response in blood [3, 49]. Host response signa-
tures can therefore be leveraged to diagnose viral infec-
tions, prior to the onset of peak clinical symptoms, and
can also differentiate between RSV, or RV and influenza
infections [48, 49].
To characterize the molecular networks underlying
symptomatic infections, we downloaded a microarray
data set from a viral challenge study in which adult vol-
unteers were inoculated with RSV, RV or IAV [3]. We
employed case/control comparisons of symptomatic versus
asymptomatic subjects to identify differentially expressed
genes for each virus, and we found that the strongest dis-
turbance of the transcriptome was induced by IAV,
followed by RV and then RSV. To provide a network-level
view of these data, we leveraged experimentally supported
molecular interaction data from prior studies to reconstruct
the wiring diagram of the underlying gene networks [50].
These networks unveil the innate immune response hubs
underlying symptomatic infections (Fig. 3a, c and e). To
identify the putative causal pathways that give rise to the
observed gene expression patterns, we employing upstream
regulator analysis [51]. This analysis suggested that symp-
tomatic responses to RSV were largely driven by IFN-λ,
IFN-γ, IFN-α and STAT3 signalling (Fig. 3b). RV responses
Fig. 2 Innate immunity is governed by a bow-tie architecture. The
bow-tie is a multilayered control system, comprising input, core and
output signals
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were also characterized by upregulation of type I, II
and III interferon signalling, but lacked a prominent
STAT3 signature (Fig. 3d). The hallmark of the IAV re-
sponse was upregulation of IFN-γ, TNF, IFN-α and IL-1β
signalling (Fig. 3f). The proinflammatory component of
the IAV response provides a plausible mechanism to ex-
plain why this virus elicits a stronger perturbation to the
transcriptome.
Fig. 3 Gene networks and molecular drivers underlying symptomatic host responses to infection. Gene expression patterns were profiled in
blood from adult volunteers after experimental infection with RSV, RV or IAV [3]. Differentially expressed were identified between symptomatic
versus asymptomatic subjects for each virus, resulting in 934 differentially expressed genes for IAV (adjusted p-value < 0.05), 173 genes for RV (adj
p-value < 0.05), and 130 genes for RSV (adj p-value < 0.1). a/c/e; Network wiring diagrams were constructed utilizing experimentally supported
findings from prior studies (Ingenuity Systems KnowledgeBase) [50]. Genes coloured red were upregulated and those coloured green were
downregulated. b/d/f; Upstream regulator analysis was employed to identify the molecular drivers of the response [51]. The negative log
p-value was shaded red to indicate pathway activation, and blue indicates inhibition
Troy and Bosco Respiratory Research  (2016) 17:156 Page 5 of 12
Pathogenesis of RSV infections
Most children with RSV develop mild symptoms such as
cough, fever, sore throat and runny nose. Up to 40% of
infants develop lower airway symptoms (e.g. shortness of
breath, wheeze, bronchiolitis) and 0.5-2% of all infected
infants are hospitalized [52]. Risk factors for severe dis-
ease include premature birth, low birth weight, young
age, male gender, chronic lung disease, congenital heart
disease, immune deficiency, low socio-economic status
and tobacco exposure [52]. The presence of pathogenic
bacteria (Streptococcus, Moraxella, Haemophilus) in the
nasopharyngeal microbiome increases the risk of the in-
fection spreading from the upper to the lower airways
and inducing more severe symptoms [53].
The pathogenesis of RSV infections is thought to be
mediated by direct cytopathic effects of the virus on lung
epithelial cells in combination with the inflammatory re-
sponse [54–56]. Airways obstruction results from epithe-
lial damage, including loss of function of motile cilia,
epithelial sloughing, apoptosis, mucous hypersecretion,
edema of the airway wall, and infiltration of neutrophils
and lymphocytes [2]. High viral load correlates with in-
creased disease severity in hospitalized infants, while
faster rates of RSV clearance are associated with more
rapid disease resolution and shorter hospitalization
[57, 58]. In differentiated epithelial cell cultures, RSV
induces a relatively mild disturbance to the transcrip-
tome, which is an order of magnitude lower than that
of IAV [59]. The RSV response in this system is mainly
restricted to an interferon signature, whereas the IAV re-
sponse comprises type I and III interferons, and a broad
range of proinflammatory cytokines and chemokines.
However, these models cannot provide insight into the
role of innate signalling from inflammatory cells that
are recruited to the airways.
A unique and perplexing feature of RSV infections is
the disproportionate impact on infants. At birth, the im-
mune and respiratory systems are functionally immature,
and susceptibility to lower respiratory illnesses can be
explained in part by diminished lung function [60, 61].
On the other hand, the neonatal innate immune system
has a reduced capacity to produce cytokines (IL-12, IFN-α,
TNF) that promote Th1 responses against intracellular
pathogens, but has a similar or augmented capacity to
produce cytokines (IL-1b, IL-6, IL-8, IL-10, IL-23) that
promote Th2 and Th17 responses [62, 63]. This defect
in Th1 function is also apparent within the CD4 T cell
compartment [60], and is thought to result in Th2- and
Th17-skewed responses to infection [64–66]. Recent
evidence from parallel studies in neonatal animal models
and in hospitalized infants suggests that RSV-induced
IL-33 responses are exaggerated in early life, which in
turn activates group 2 innate lymphoid cells (ILC2) that
drive Th2-associated pathology (eosinophilic inflammation,
mucus hypersecretion, airway hyperresponsiveness) [67].
Th1/Th2 imbalance during RSV bronchiolitis is modified
by interactions between TLR4 genotype and environmental
LPS exposure levels, thus explaining in part why some indi-
viduals are predisposed to severe disease [68].
Gene network patterns in blood have been investigated
in a cohort of hospitalized infants with RSV, RV or IAV
[69]. RSV response networks were characterized by up-
regulation of interferon signalling, innate immunity and
neutrophil/myeloid signatures, and downregulation of
lymphocyte signatures (T cells, B cells, NK cells). Notably,
interferon responses continued to rise at one month after
hospitalization, whereas expression of the other networks
faded. Compared with RV or IAV, RSV was associated
with overexpression of neutrophil genes and marked
suppression of lymphocyte genes. Younger infants
(<6 months) with RSV had impaired innate immune and
inflammatory responses compared with older infants. The
severity of RSV illness was correlated with heightened ex-
pression of networks related to neutrophils, inflammation
and erythrocytes, whereas innate immune and interferon
responses were similar in moderate and severe infants. Fi-
nally, length of hospitalization and total duration of sup-
plemental oxygen was strongly correlated with the extent
at which the transcriptome was perturbed in infants with
RSV illness relative to healthy baseline controls. These
findings implicate excessive activation of neutrophil and
inflammatory responses in the pathogenesis of severe RSV
disease.
Pathogenesis of RV infection
RV is the most important trigger of asthma exacerba-
tions, however, it is frequently detected in children with
asthma in the absence of significant symptoms [4]. This
suggests that specific environmental conditions are neces-
sary for RV to provoke exacerbations [70]. Natural aller-
gen exposure in sensitized subjects markedly increases
risk for experiencing a severe exacerbation with RV [71].
Pathogenic bacteria can also increase the severity of RV
infections [72]. Another contributing factor is the virus it-
self. RV-C is the most common virus found in children
presenting to hospital with acute asthma [73]. RV-C-
induced exacerbations are more severe, and associated
with an increased risk of recurrence, especially in atopics
[73, 74]. A variant in CDHR3 (Cys529→Tyr, rs6967330)
that enhances RV-C binding and replication by 10-fold is
associated with recurrent severe exacerbations [19, 75].
RV-B species on the other hand have reduced replication
rates, elicit lower levels of cytokine production, and induce
less severe respiratory symptoms compared with RV-A
and RV-C [76, 77]. Antibody responses to RV-C are much
lower than RV-A or RV-B, providing further evidence that
RV species elicit differential immune responses [78].
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There is evidence suggesting that genetic variation
modulates host responses to RV and the expression of
respiratory symptoms [79, 80]. Variants in the 17q21
locus are associated with RV-induced wheezing but not
RSV-induced wheezing [80]. Although the underlying
mechanisms are unknown, expression levels of only two
genes (ORMDL3, GSDMB) in this region are induced by
RV and are correlated with the 17q variants [80]. Trans-
genic overexpression of human ORMDL3 in mice results
in increased levels of airways remodelling, a hallmark of
asthma [81]. Of note, a unique aspect of the airway epi-
thelial cell response to RV is the induction of a broad
range of genes involved in epithelial repair and remodel-
ling [82, 83]. In vitro studies have shown that the cap-
acity of the airway epithelium to repair is impaired in
subjects with asthma, and this capacity diminishes even
further in the presence of RV [84]. These data highlight
a potential role for dysregulated repair and remodelling
in the pathogenesis of RV infections.
Numerous studies have investigated the role of innate
immunity in asthma. Ex vivo studies in airway epithelial
cells found that RV-induced IFN-β and IFN-λ responses
were impaired in subjects with asthma, leading to in-
creased viral replication and shedding and exaggerated
secondary responses [85, 86]. However, this finding was
replicated by some groups but not others (reviewed
[87]). A simple explanation for these inconsistent find-
ings is that asthma is a highly heterogeneous disease that
can be divided into Th2High versus Th2Low subgroups [88].
Given that type I and III interferon and Th2 responses are
mutually antagonistic, variations in airway epithelial cell
responses to RV ex vivo may reflect the nature of the in-
flammatory microenvironment that was present during
specimen collection rather than a defect in the capacity to
respond to viruses [89–93]. Indeed, genomic studies in
peripheral blood mononuclear cells (PBMC) have found
that asthma exacerbations are heterogeneous conditions
and comprise at least three molecular subphenotypes [94].
The first phenotype was characterized by activation of
innate immunity genes. The second was enriched with
antigen driven pathways of adaptive immunity and the
third was not associated with any dominant biological
pathways. An alternative explanation for impaired inter-
feron responses in subjects with asthma is decreased ex-
pression of pathways that promote these responses (e.g.
TLR7) or increased expression of pathways that inhibit
these responses (e.g. SOCS1) [29, 95].
We have characterized the inflammatory mechanisms
that underpin virus-induced asthma exacerbations in vivo.
We found that interferon gene networks were upregulated
in the upper (nasal wash) and lower (sputum) airways of
children during acute asthma exacerbations compared to
7–14 days later [50, 96]. However, expression of Th1 and
type I interferon gene networks was reduced in those
asthmatic children with evidence of chronic airflow limita-
tion, suggesting a protective role for interferons [96].
Other groups have reported that expression of interferons
is increased and correlated with expression of respiratory
symptoms during naturally acquired RV-induced exacer-
bations [97, 98]. Taken together, these studies highlight
the potential for interferons to play a dual role in asthma,
in both the regulation of antiviral immunity and expres-
sion of respiratory symptoms [99]. Variable expression of
interferon production in asthma may also be related to
viral susceptibility or loads, or variations in the timing
from infection onset to peak symptom expression.
Genomic studies from our group found that childhood
asthma exacerbation responses in PBMC were associated
with upregulation of innate immune and Th2-associated
signatures, suggesting that these two pathways interact
to drive disease pathogenesis [100]. The mechanisms
that link innate antiviral responses with Th2-associated
effector mechanisms are not well understood, but recent
studies suggest a role for IL-25 and IL-33. Expression of
both of these factors is increased in the airways of asth-
matic subjects after experimental RV infection in vivo
[101, 102]. In allergic mice, blockade of IL-25 signalling
markedly suppressed RV-induced production of mucus
and airways inflammation [101]. Moreover, supernatants
from RV-infected bronchial epithelial cells stimulate Th2
cytokine production in Th2 and ILC2 cells in an IL-33
dependant manner [102]. The mechanisms that regulate
the production of IL-25 and IL-33 during RV infections
are not well understood. Employing siRNA-mediated
gene silencing, we found that IRF7 promotes innate anti-
viral responses to RV in airway epithelial cells, and limits
IL-33 responses [103]. These data are consistent with
the mutually antagonistic relationship between the inter-
feron and Th2 response system described above.
Pathogenesis of IAV infections
IAV is ranked amongst the top 10 causes of death in the
USA [7]. Mortality rates can be even higher during pan-
demics such as the 1918 “Spanish Flu”, which resulted in
an estimated 50 million deaths [104]. Symptoms of influ-
enza include fever, headache, sore throat, sneezing, nausea,
body aches and fatigue. Risk factors for severe disease
include old age, very young age, pregnancy, immune
deficiency and chronic diseases like asthma, COPD and
obesity [105]. The pathogenesis of IAV infections is
thought to be determined by cell tropism for human
airway and alveolar epithelial cells, viral replication rate
and the intensity and dynamics of the inflammatory re-
sponse [105]. Large swathes of epithelium are denuded
or damaged by IAV infection, resulting in exudation of
fluid into the airways and alveolar spaces, and in severe
cases this can lead to hypoxaemia and respiratory fail-
ure [105]. A robust repair response is crucial to restore
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the epithelial barrier and lung microarchitecture following
viral clearance [106]. However, the mechanisms that act to
resolve inflammation and restore tissue homeostasis
also impair immunity, and this increases susceptibility
to secondary bacterial pneumonia, especially during
pandemics [107].
Host responses to IAV infection in the lung are highly
dynamic and comprise multiple sequential waves of gene
expression, and similar findings have been reported in
blood [108, 109]. The first wave peaks around 2–5 days
post infection, and is characterized by upregulation of
innate immune networks, interferon and NK cell re-
sponses, and proinflammatory cytokines and chemokines.
The next wave spikes on day 8 post infection, and this is
defined by upregulation of T cell activation and induction
of apoptosis. This is followed by upregulation of B cell ac-
tivation and proliferation, which is maximal around day
14. On day 30, differentiation and tissue repair processes
are upregulated, and these responses persist out to 60 days
post infection, suggesting long term or permanent alter-
ations to the lung [108]. Notably, restoration of epithelial
barrier integrity and lung function after IAV infection de-
pends on an IL-33-ILC2-amphiregulin axis [110]. This
contrasts with the known pathogenic role of IL-33/ILC2
in the context of RSV and RV illness.
The biology of asymptomatic IAV infections is poorly
understood. Viral challenge studies are particularly in-
formative in this context, because only a subset of the
participants develops symptoms and has evidence of
viral shedding [3, 111]. Of the remaining asymptomatic
subjects, a subset of them has detectable viral shedding,
albeit levels are lower and delayed in onset [111]. The
temporal dynamics of the host response to IAV in blood
is strikingly different in symptomatic versus asymptom-
atic subjects [111]. Expression of clinical symptoms is
strongly associated with upregulation of viral sensing
pathways and interferon-stimulated genes, as well as
neutrophil activation, proinflammatory responses and
inflammasome signaling (NOD2, NALP3, CASP5, IL-1b)
[111]. In contrast, a hallmark of the asymptomatic response
was upregulation of pathways that restrain cytokine signal-
ing (SOCS2, SOCS5) and oxidative stress (SOD1, STK25),
together with suppression of inflammasome signaling path-
ways. Of note, myeloid derived suppressor cells (MDSC)
accumulate in the lung during IAV infections, and may
contribute to the immunosuppressive environment via pro-
duction of IL-10 [112, 113]. These findings suggest that a
unique host response is mobilized during asymptomatic in-
fections, and this could potentially be leveraged to develop
novel therapeutics.
Genomic studies of host responses to highly patho-
genic avian H5N1 virus and the 1918 (H1N1) pandemic
virus have provided unique insights into disease patho-
genesis. The 1918 virus was recreated from the genomic
sequence using reverse genetics [114]. In mice and cyno-
molgus macaques, 1918 infection results in a lethal disease
phenotype, which is characterized by high viral titers, se-
vere lung pathology and marked and sustained activation
of interferon-stimulated genes and pro-inflammatory
cytokines and chemokines until death [115, 116]. Not-
ably, expression of multiple type I interferon subtypes
was suppressed despite high levels of ISGs, suggesting
that the 1918 virus elicits an aberrant interferon re-
sponse, and/or has reduced sensitivity to the interferon
system. Highly pathogenic avian H5N1 infections are
also characterized by severe lung pathology together
with early and sustained activation of proinflammatory
and interferon responses [117, 118]. One interpretation
of these data is that although a robust innate immune
response becomes activated, it is not able to control the
virus, resulting in death due to direct viral damage to
the airways. An alternative view is that an unconstrained
“cytokine storm” drives lethal disease [119]. With regards
to the former hypothesis, the virulence of the 1918 viral
proteins has been demonstrated by introducing them into
less pathogenic strains. These experiments found that the
1918 HA protein confers high viral loads and aberrant
host responses resulting in mortality, whereas the poly-
merase and NP proteins confers high viral loads, but does
not induce lethal disease [120]. The NS1 protein blocks
interferon signaling and lipid metabolism, the PB2 protein
enhances inflammation and suppresses pathways involved
in lung repair [121, 122] and a mutation in the 1918 NP
protein confers resistance to Mx1 [123]. These data shed
light on the exceptional virulence of the 1918 virus. With
regards to the cytokine storm hypothesis, attempts to
curtail the 1918-induced host response using gene defi-
cient mice can prolong (Nos2−/−, TNFR−/−) or shorten
(IL1R1−/−, IFNAR1−/−) survival, but does not prevent
mortality [118, 124, 125]. In contrast, therapy with the
ROS scavenger EUK-207 increased survival in mice with
1918 [126].
It is important to acknowledge that the findings from
gene deficient mice are oversimplified, because immune
mechanisms that are important in viral control may also
damage the host, and this dual role of the immune sys-
tem may be dependent on the timing and magnitude of
gene expression. In this context it is noteworthy that lethal
influenza in mice is associated with excessive activation of
neutrophils. Increased survival in this model was achieved
by attenuating rather than ablating the neutrophil re-
sponse, without compromising viral clearance [127].
Conclusions
The pathogenesis of respiratory viral infections involves
the complex interplay between viral virulence factors,
environmental conditions, the magnitude and temporal
dynamics of the host response, and host susceptibility
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factors. Symptomatic infections are associated with in-
creased viral shedding and a heightened host immune
response. The disproportionate impact of respiratory
viral infections in early life and in individuals with
chronic respiratory diseases like asthma can be explained
by an aberrant host response. It is also apparent that the
immune response whilst essential for viral control also
promotes the expression of respiratory symptoms and
causes collateral damage to the tissues, which in some
cases can lead to mortality. This dual role of the immune
system can be difficult to dissect using conventional
knockout mouse models, thus more systems-levels ana-
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